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Quantifying the Importance of Interleukin-6 
for Coronary Heart Disease
Bruce Neal
F
or many years it was widely 
believed that known vascular 
risk factors could explain only 
about half of all cardiovascular disease 
[1], leaving much to be discovered 
about other causes of stroke and heart 
attack. There has been considerable 
interest in the possible aetiological role 
of inﬂammation in vascular disease. 
Interleukin-6 (IL-6) is one of a number 
of inﬂammatory markers that have 
been studied [2]. There are, however, 
substantial and often unrecognised 
challenges to quantifying the full 
effects of risk factors such as IL-6. 
A particular problem in establishing 
the true nature of the association 
between exposures and outcomes arises 
from the difﬁculty of achieving a good 
estimate of the true level of the risk 
factor of interest. It is very difﬁcult to 
establish an individual’s usual level of 
exposure to an inﬂammatory marker 
such as IL-6, because it has a short 
half life and is complex to assay. The 
same challenge also applies to well-
established, and apparently easier to 
measure, determinants of risk such 
as blood pressure and cholesterol 
because they also ﬂuctuate substantially 
over relatively short time periods [3]. 
Therefore a key strength of a new 
study by John Danesh and colleagues, 
reported in this issue of PLoS Medicine 
[4], is the substantial effort undertaken 
to overcome this problem and obtain 
reliable estimates of the association 
between IL-6 and coronary heart 
disease [5]. Whether the ﬁndings for 
IL-6 provide substantial new insight 
into the causation of cardiovascular 
disease is, however, rather less clear.
The New Study
Danesh and colleagues present 
new data on IL-6 levels from two 
population-based prospective cohorts, 
the Reykjavik Study and the British 
Regional Heart Study (BRHS), which 
together involve 24,230 mostly middle-
aged individuals with an average 
of almost 20 years of follow-up per 
participant [5]. After excluding 
participants with any evidence of 
baseline cardiovascular disease, 2,138 
incident cases of coronary heart disease 
(CHD) were available for analysis. 
The researchers evaluated associations 
between long-term circulating IL-
6 levels and CHD risk in these two 
population-based cohorts. They then 
used ﬁndings from these two new 
studies to update a systematic review 
of all prospective, population-based 
studies on IL-6 and CHD published 
before May 2007.
Controlling for Imprecise 
Measurement of IL-6
In epidemiological studies, imprecise 
measurement of an exposure of 
interest leads to underestimation of 
the strength of the association with 
the outcome [5]. The bias caused by 
random error in measuring exposure 
was ﬁrst highlighted in the 1990s in 
reports relating blood pressure levels 
to vascular risk, in which imprecise 
measurement of blood pressure was 
shown to substantially underestimate 
the strength of the association with 
both stroke and heart attack [3]. 
Since those ﬁrst reports, a number 
of approaches have been developed 
to control for “regression dilution 
bias” [6]. The associations of IL-6 with 
coronary heart disease reported by 
Danesh and colleagues were adjusted 
using an established technique based 
upon repeated assays of IL-6 done 
several years apart in a sample of 
participants. Adjustments for errors 
in exposure measurement were also 
made for the covariates included in the 
multivariable models ﬁtted to the data 
from the Reykjavik and BRHS studies, 
providing for uniquely powerful 
adjustment of potential confounders 
of the association of IL-6 with CHD. As 
such, the results provide a particularly 
reliable estimate of the strength of 
the association of IL-6 with CHD and 
establish a standard against which 
future studies of association might be 
judged.
New Evidence about the Effects of 
IL-6
The association of IL-6 with the risk of 
CHD was found to be similar in nature 
and magnitude to that of a number 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS 
Medicine:
Danesh J, Kaptoge S, Mann AG, Sarwar 
N, Wood A, et al. (2008) Long-term 
interleukin-6 levels and subsequent 
risk of coronary heart disease: Two new 
prospective studies and a systematic 
review. PLoS Med 5(4): e78. doi:10.1371/
journal.pmed.0050078
John Danesh and colleagues show 
that long-term IL-6 levels are associated 
with coronary heart disease risk, thus 
highlighting the potential relevance of IL-
6–mediated pathways to coronary heart 
disease.
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of major established determinants of 
vascular disease. The comparability 
of the ﬁndings of the Reykjavik study 
to those of the BRHS study provides 
reassurance that these ﬁndings are 
unlikely to be simply the result of 
chance. Likewise, when viewed in the 
context of the 15 other studies of IL-6 
included in the meta-analysis, there 
was striking similarity in the direction 
of association across the different 
studies. There was some variability 
between studies in the magnitude of 
the associations observed that is not 
explained by Danesh and colleagues’ 
exploratory analyses. However, the 
analytic options available to explore 
heterogeneity in the strength of 
association are limited, and the meta-
regression technique used by Danesh 
and colleagues would not have provided 
great power to detect effects of study 
level characteristics. It therefore 
remains possible that variation in the 
techniques used for the collection, 
storage, and analysis of the blood 
samples on which the IL-6 assays were 
done could have inﬂuenced differently 
the magnitude of association identiﬁed 
in each of the contributing studies.
In addition to the association 
with CHD, IL-6 levels were also 
strongly associated with a number 
of established risk factors and other 
inﬂammatory markers. For example, 
there were moderate associations 
of IL-6 with smoking, diabetes, and 
dyslipidaemia. Accordingly the 
strength of the association between 
IL-6 and CHD varied between models 
including different sets of covariates 
and was attenuated when covariates 
strongly correlated with IL-6 were 
included. While the position of IL-6 
in the causal pathway of some of the 
covariates included in the models is 
reasonably well understood, the patho-
physiological relationship with other 
of the established determinants of 
vascular risk is less clear. The extent 
to which IL-6 might account for 
previously unexplained vascular risk 
cannot be quantiﬁed from these data. 
However, it seems unlikely that IL-6 
makes a major contribution to vascular 
disease causation that is completely 
independent of the many other risk 
factors already identiﬁed.
Clinical Implications
While impressive in their rigour, the 
ﬁndings from this study are probably 
rather limited in regard to their 
clinical implications. Future studies 
of interventions for the control of 
vascular disease might gain insight into 
mechanisms of action through assay of 
IL-6. Likewise, IL-6 could be a target 
for the development of new chemical 
entities designed to modify vascular 
disease progression. 
There are, however, almost certainly 
better foci of attention than IL-6 for 
physicians, researchers, and policy 
makers seeking to reduce the huge 
global burden of vascular disease 
[7]. It is now widely accepted that 
90% or more of vascular disease can 
be explained on the basis of known 
risk factors, so these new data about 
IL-6 probably have relatively little to 
add in terms of our understanding of 
causation [8]. There are also multiple 
interventions that modify these known 
risks and avert premature death and 
disability from vascular disease at low 
cost. Therefore there is little need for 
a new and probably costly drug that 
acts via IL-6. The better application 
of proven risk stratiﬁcation methods 
and the more efﬁcient delivery 
of proven management strategies 
could already cut a swathe through 
the current vascular disease burden 
[9]. These proven strategies should 
remain the priority, particularly in 
developing regions of the world where 
most vascular disease now occurs. A 
focus on the identiﬁcation of practical 
strategies for the delivery of existing 
interventions could deliver hugely cost-
effective global health gains [10].  
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